GlassScriptPhysician profile
Roy J Gandolfi
NPI 1740211101
$12,276.89
in general payments reported to CMS, 2019-2025
42 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,831 · 2020: $421 · 2021: $19.16 · 2022: $3,684 · 2023: $686 · 2024: $4,259 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,000 · Food and Beverage: $1,508 · Travel and Lodging: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,000.00 |
| Food and Beverage | $1,507.97 |
| Travel and Lodging | $812.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gen-Probe, INC. | $6,081.11 | 2022-2024 | Aptima |
| Medtronic Minimed, INC. | $834.24 | 2019 | |
| Hologic Sales and Service, LLC | $611.95 | 2024 | Aptima, Btx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.97 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Gen-Probe Sales & Service, INC. | $533.20 | 2022 | |
| Amgen INC. | $441.19 | 2019-2024 | Prolia, Evenity |
| Pfizer INC. | $326.67 | 2019-2024 | |
| Glaxosmithkline, LLC. | $292.53 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $232.96 | 2019-2020 | |
| Novo Nordisk INC | $231.40 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $206.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $196.60 | 2019-2023 | Breztri |
| Novartis Pharmaceuticals Corporation | $188.76 | 2019-2024 | |
| Astellas Pharma US INC | $151.63 | 2020-2024 | Veozah, Myrbetriq, Cresemba |
| Lilly USA, LLC | $148.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Gandolfi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.